1st Quarterly Report for Diamyd Medical AB (publ), Fiscal Year 2006/2007
(SWEDEN OMX: DIAM B; USA ADR: DMYDY)September 1, 2006 – November 30, 2006• Professor Johnny Ludvigsson, Linkoping, Sweden presented clinical results from our study in type 1 diabetes patients at the European Diabetes meeting EASD in Copenhagen, Denmark in September:o Diamyd® demonstrated a clear and statistically significant protective effect on endogenous beta cell function in recent onset type 1 diabetes patients.o Diamyd® administration is very easy, only two injections required.o No serious adverse events related to Diamyd® treatment have been reported.• US clinical program